Telomir Pharmaceuticals, Inc. Retained Earnings
Telomir Pharmaceuticals, Inc. (TELO) had Retained Earnings of -$43.72 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$43.72M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$42.00M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$41.01M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$38.95M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$43.72M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$42.00M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$41.01M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$38.95M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$37.85M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$32.78M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$30.60M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$27.70M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$21.77M 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$20.32M 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$14.06M 10-K · filed 2025-02-04 |
| 2022-12-31 | -$992.28K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |